Actionable news
All posts from Actionable news
Actionable news in TROV: TrovaGene, Inc.,

Clinical Data Featuring TrovageneS Precision Cancer Monitoring Platform To Be Presented At The

The following excerpt is from the company's SEC filing.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Interim results from a colorectal cancer study adds to the body of clinical evidence supporting Trovagenes urinary ctDNA platform for the detection and monitoring of actionable oncogene mutations using a non-invasive sample

SAN DIEGO, CA November 6, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the presentation of clinical data featuring the use of its Precision Cancer Monitoring

(PCM) platform for monitoring treatment response in patients diagnosed with m etastatic colorectal cancer. Afsaneh Barzi, M.D., Ph.D., University of Southern California (USC) Norris Comprehensive Cancer Center, will present the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on November 7, 2015, in Boston. The data are an interim analysis from an ongoing 30-patient, blinded biomarker study.

This proof-of-concept study demonstrates the value of longitudinal monitoring of

mutations in metastatic colorectal cancer patients using Trovagenes urine-based liquid biopsy technology, stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. Similar to what we have observed in lung cancer studies, these data demonstrate that increases in urinary ctDNA

signal, in metastatic colorectal cancer patients, were observed two months prior to imaging and decreases were seen within two weeks of starting chemotherapy.

The dynamics of ctDNA

mutation load in urine correlated with radiographic responses, especially in liver-dominant metastatic patients, stated Dr. Barzi. This suggests that urinary ctDNA may be a valuable method for monitoring treatment responses in patients with metastatic colorectal cancer.

Abstract title:

Use of urinary circulating tumor DNA (ctDNA) KRAS for monitoring treatment response in patients with metastatic colorectal cancer (mCRC)

Abstract No.


Afsaneh Barzi, M.D., Ph.D., Assistant Professor of Clinical Medicine, Keck School of Medicine of USC